home All News open_in_new Full Article

U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults

  Not intended for UK audiences  Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 Affecting up to 100,000 people in the U.S. and up to 5.6 million worldwide, PPF is linked to an underlying clinical interstitial lung disease (ILD) diagnosis, such as autoimmune ILD or hypersensitivity […]


today 5 h. ago attach_file Economics

attach_file Science
attach_file Culture
attach_file Other
attach_file Politics
attach_file Culture
attach_file Sport
attach_file Other
attach_file Economics
attach_file Other
attach_file Science
attach_file Economics
attach_file Other
attach_file Science
attach_file Politics
attach_file Events
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Science


ID: 1259929878
Add Watch Country

arrow_drop_down